Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Avapritinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 439,452Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Blueprint Medicines Raises AYVAKIT® Revenue Guidance for 2024
    Blueprint Medicines Raises AYVAKIT® Revenue Guidance for 2024

    30 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/blueprint-medicines-reports-third-quarter-2024-results-and-raises-ayvakitayvakyt-avapritinib-full-year-revenue-guidance-302290815.html

    PR NEWSWIRE
    30 Oct 2024
    Share Share
    Blueprint Medicines to Present at Upcoming Investor Conferences
    Blueprint Medicines to Present at Upcoming Investor Conferences

    10 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-upcoming-investor-conferences-302232128.html

    PR NEWSWIRE
    10 Sep 2024
    Share Share
    Blueprint AYVAKIT Data At EAACI EHA Highlight Sustained Benefit
    Blueprint AYVAKIT Data At EAACI EHA Highlight Sustained Benefit

    30 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/blueprint-medicines-announces-data-presentations-at-eaaci-and-eha-annual-meetings-highlighting-sustained-clinical-benefits-of-ayvakitayvakyt-avapritinib-302160044.html

    PR NEWSWIRE
    30 May 2024
    Share Share
    Blueprint Reports Strong Q1 2024, Raises AYVAKIT® Revenue Guidance
    Blueprint Reports Strong Q1 2024, Raises AYVAKIT® Revenue Guidance

    02 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/blueprint-medicines-reports-strong-first-quarter-2024-results-and-raises-ayvakitayvakyt-avapritinib-full-year-revenue-guidance-302133890.html

    PR NEWSWIRE
    02 May 2024
    Share Share
    Blueprint Medicines Highlights AYVAKIT Long-Term Efficacy and Safety Data
    Blueprint Medicines Highlights AYVAKIT Long-Term Efficacy and Safety Data

    23 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/blueprint-medicines-highlights-ayvakit-avapritinib-long-term-efficacy-and-safety-data-and-advances-in-mast-cell-disease-research-at-2024-aaaai-annual-meeting-302069445.html

    PR NEWSWIRE
    23 Feb 2024
    Share Share
    Blueprint boosts Ayvakit peak sales estimate to $2B
    Blueprint boosts Ayvakit peak sales estimate to $2B

    15 Feb 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/blueprint-boosts-ayvakit-peak-sales-estimate-2b-key-rare-disease-expansion-accelerates

    FIERCE PHARMA
    15 Feb 2024
    Share Share